|
End-of-day quote
NEO Exchange
15/09/2026
|
5-day change | 1st Jan Change | ||
| 11.20 CAD | -0.18% |
|
-6.51% | +10.45% |
| 12:39am | Novo Nordisk to Collaborate With Anthropic to Help Accelerate Drug Discovery, Development | MT |
| 12:24am | Workers are spending £1 billion to buy their own AI tools for work | RE |
Company Valuation: NVIDIA Corporation
Data adjusted to current consolidation scope
| Fiscal Period: January | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,58,100 | 4,75,539 | 15,21,940 | 34,92,764 | 45,60,193 | 51,23,269 | - | - |
| Change | - | -14.79% | 220.05% | 129.49% | 30.56% | 12.35% | - | - |
| Enterprise Value (EV) 1 | 5,47,838 | 4,73,196 | 15,05,665 | 34,49,554 | 45,06,105 | 49,65,116 | 47,84,033 | 45,15,288 |
| Change | - | -13.62% | 218.19% | 129.11% | 30.63% | 10.19% | -3.65% | -5.62% |
| P/E | 58x | 111x | 51.6x | 48.5x | 38.3x | 21.3x | 13.6x | 10.6x |
| PBR | 21.3x | 21.9x | 35.8x | 44.6x | 29.2x | 17x | 9.58x | 6.02x |
| PEG | - | -2x | 0x | 0x | 0.6x | 0x | 0.2x | 0.4x |
| Capitalization / Revenue | 20.7x | 17.6x | 25x | 26.8x | 21.1x | 12.5x | 7.53x | 5.75x |
| EV / Revenue | 20.4x | 17.5x | 24.7x | 26.4x | 20.9x | 12.1x | 7.04x | 5.06x |
| EV / EBITDA | 48.8x | 82x | 43.7x | 41.4x | 32.2x | 18.3x | 10.7x | 7.57x |
| EV / EBIT | 43.2x | 52.3x | 40.5x | 39.7x | 32.8x | 18.5x | 10.6x | 7.5x |
| EV / FCF | 67.4x | 124x | 55.7x | 56.7x | 46.6x | 25.6x | 14.8x | 10.2x |
| FCF Yield | 1.48% | 0.8% | 1.79% | 1.76% | 2.15% | 3.91% | 6.77% | 9.77% |
| Dividend per Share 2 | 0.016 | 0.016 | 0.016 | 0.07 | 0.04 | 0.7573 | 1.091 | 1.214 |
| Rate of return | 0.07% | 0.08% | 0.03% | 0.05% | 0.02% | 0.36% | 0.51% | 0.57% |
| EPS 2 | 0.385 | 0.174 | 1.193 | 2.94 | 4.9 | 9.942 | 15.55 | 19.94 |
| Distribution rate | 4.16% | 9.2% | 1.34% | 2.38% | 0.82% | 7.62% | 7.01% | 6.09% |
| Net sales 1 | 26,914 | 26,974 | 60,922 | 1,30,497 | 2,15,938 | 4,11,479 | 6,80,030 | 8,91,748 |
| EBITDA 1 | 11,215 | 5,768 | 34,480 | 83,317 | 1,40,143 | 2,71,568 | 4,47,752 | 5,96,721 |
| EBIT 1 | 12,690 | 9,040 | 37,134 | 86,789 | 1,37,300 | 2,68,846 | 4,50,387 | 6,02,064 |
| Net income 1 | 9,752 | 4,368 | 29,760 | 72,880 | 1,20,067 | 2,42,389 | 3,76,287 | 4,75,493 |
| Net Debt 1 | -10,262 | -2,343 | -16,275 | -43,210 | -54,088 | -1,58,153 | -3,39,236 | -6,07,981 |
| Reference price 2 | 22.32 | 19.32 | 61.62 | 142.62 | 187.67 | 212.17 | 212.17 | 212.17 |
| Nbr of stocks (in thousands) | 2,50,00,000 | 2,46,10,000 | 2,47,00,000 | 2,44,90,000 | 2,42,99,000 | 2,41,47,000 | - | - |
| Announcement Date | 16/02/22 | 22/02/23 | 21/02/24 | 26/02/25 | 25/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 21.34x | 12.07x | 18.28x | 0.36% | 5,12300Cr | ||
| 22.21x | 10.89x | 14.76x | 1.14% | 1,93900Cr | ||
| 36.8x | 15.52x | 22.8x | 0.77% | 1,62000Cr | ||
| 12.76x | 7.74x | 9.35x | 0.06% | 1,04800Cr | ||
| 4.84x | 3.05x | 3.69x | 0.21% | 90TCr | ||
| 88.2x | 15.93x | 60.55x | -.--% | 82TCr | ||
| -42.09x | 8.45x | 23.53x | -.--% | 51TCr | ||
| 191.82x | 41.98x | 85.51x | -.--% | 26TCr | ||
| Average | 41.99x | 14.45x | 29.81x | 0.32% | 1,52800Cr | |
| Weighted average by Cap. | 27.03x | 12.04x | 20.96x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NVDA Stock
- ZNVD Stock
- Valuation NVIDIA Corporation
Select your edition
All financial news and data tailored to specific country editions
















